Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 3Lymphoma, B-Cell 3Lymphoma, Mantle-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 77Cyclophosphamide 54fludarabine phosphate 50Peripheral Blood Stem Cell Transplantation 44Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 25Cyclosporine 23Busulfan 22Bortezomib 22Dexamethasone 21Etoposide 19ibrutinib 18Melphalan 17Antilymphocyte Serum 17Methotrexate 15Lenalidomide 15Filgrastim 14Radiotherapy 12Bendamustine Hydrochloride 12Sirolimus 10Calcium Dobesilate 10Flow Cytometry 9Everolimus 9Cyclosporins 9zanubrutinib 8Alemtuzumab 7ibritumomab tiuxetan 6Transplantation 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Waldenstrom Macroglobulinemia × loncastuximab tesirine × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡